Supporting clinical relevance, high FGD3 expression strongly correlated with improved relapse-free survival in breast cancer patients after chemotherapy and this correlation was stronger than was seen for NINJ1 and other proteins associated with lytic cell death. The gene discussed is FGD3; the disease is breast carcinoma.